A prospective evaluation of the effect of chronic proton pump inhibitor use on plasma biomarker levels in humans

Pancreas

Volumn 41, Issue 4, 2012, Pages 508-511

  Raines, Daniel ^a   Chester, Maria ^a   Diebold, Anne E ^a   Mamikunian, Paris ^b   Anthony, Catherine T ^a   Mamikunian, Gregg ^b   Woltering, Eugene A ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Inter Science Institute   (United States)

Author keywords

chromogranin A; gastrin; neuroendocrine tumor (NET; pancreastatin

Indexed keywords

CHROMOGRANIN A; ESOMEPRAZOLE; GASTRIN; OMEPRAZOLE; PANCREASTATIN; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GASTRIN BLOOD LEVEL; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; CHROMOGRANIN A; FEMALE; GASTRINS; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; PANCREAS; PANCREATIC HORMONES; PANCREATIC NEOPLASMS; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84859965815     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e318243a0b6     Document Type: Article

References (12)

1. Laine L, Ahnen D, Mcclain C, et al. Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther. 2000;14(6):651-668. (Pubitemid 30352732)
2. Woltering EA, Hilton RS, Zolfoghary CM, et al. Validation of serum versus plasma measurements of chromogranin A levels in patients with carcinoid tumors: lack of correlation between absolute chromogranin a levels and symptom frequency. Pancreas. 2006;33(3):250-254. (Pubitemid 44470140)
3. Vinik AI, Silva MP, Woltering EA, et al. Biochemical testing for neuroendocrine tumors (NETs). Pancreas. 2009;38(8):876-889.
4. O'Dorisio TM, Krutzik SR, Woltering EA, et al. Development of a highly sensitive and specific carboxy-terminal human pancreastatin assay to monitor neuroendocrine tumor behavior. Pancreas. 2010;39(5):611-616.
5. Giusti M, Sidoti M, Augeri C, et al. Effect of short-term treatment with low dosages of the proton-pump inhibitor omeprazole on serum chromogranin A levels in man. Eur J Endocrinol. 2004;150(3):299-303. (Pubitemid 38443779)
6. Winsett OE, Townsend CM Jr, Glass EJ, et al. Gastrin stimulates growth of colon cancer. Surgery. 1986;99(3):302-307. (Pubitemid 16026973)
7. Joseph S, Wang YZ, Boudreaux JP, et al. Neuroendocrine tumors: current recommendations for diagnosis and surgical management. Endocrinol Metab Clin North Am. 2010;40:205-231.
8. Glantz SA. The special case of two groups: the t test. In: Primer of Biostatistics. 6th ed. New York, NY: McGraw-Hill; 2005:73-125.
9. Hou W, Schubert ML. Treatment of gastric carcinoids. Current Treatment Options in Gastroenterology. 2007;10:123-133. (Pubitemid 46579160)
10. Burkitt MD, Pritchard DM. Review article: pathogenesis and management of gastric carcinoid tumors. Aliment Pharmacol Ther. 2006;24(9):1305-1320. (Pubitemid 44571561)
11. Gibril F, Jensen RT. Zollinger-Ellison syndrome revisited: diagnosis, biologic marker, associated inherited disorders, and acid hypersecretion. Curr Gastroenterol Rep. 2004;6:454-463. (Pubitemid 39591825)
12. DeHerder WW. Biochemistry of NETS. Best Pract Res Clin Endocrinol Metab. 2007;22:33-41.